Azuka Patrick Okwuraiwe

Dr. Azuka Patrick Okwuraiwe

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
IOIdowu Bolade Olawoye
Idowu Bolade Olawoye
POPaul Oluniyi
Paul Oluniyi
JOJudith Oguzie
Judith Oguzie
JUJessica N. Uwanibe
Jessica N. Uwanibe
AKAdeyemi Kayode
Adeyemi Kayode
THT. Happi
T. Happi
Identifying the dissemination patterns and impacts of a virus of economic or health importance during a pandemic is crucial, as it informs the public on policies for containment in order to reduce the spread of the virus. In this study, we integrated genomic and travel data to investigate the emergence and spread of the SARS-CoV-2 B.1.1.318 and B.1.525 (Eta) variants of interest in Nigeria and the wider Africa region. By integrating travel data and phylogeographic reconstructions, we find that these two variants that arose during the second wave in Nigeria emerged from within Africa, with the B.1.525 from Nigeria, and then spread to other parts of the world. Data from this study show how regional connectivity of Nigeria drove the spread of these variants of interest to surrounding countries and those connected by air-traffic. Our findings demonstrate the power of genomic analysis when combined with mobility and epidemiological data to identify the drivers of transmission, as bidirectional transmission within and between African nations are grossly underestimated as seen in our import risk index estimates.

24 July 2025 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
AEAdaeze E. Egwudo
Adaeze E. Egwudo
Ayodapo JegedeAyodapo Jegede
Ayodapo Jegede
TOTolulope A. Oyeniyi
Tolulope A. Oyeniyi
NENkolika Jacinta Ezekwelu
Nkolika Jacinta Ezekwelu
SASamirah N. Abdu-Aguye
Samirah N. Abdu-Aguye
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Integrating digital health technologies (DHTs) in Nigeria’s healthcare system holds promise, yet the opportunities, challenges, and strategies influencing their success remain insufficiently explored. This scoping review aimed to map these factors, focusing on healthcare settings in Nigeria. A comprehensive search of databases (PubMed, Scopus, Web of Science, and CINAHL) and Google Scholar identified publications on DHT use in Nigeria from July 1, 2014, to June 30, 2024. A total of 31 observational and experimental studies were included involving healthcare workers, patients, caregivers, or other stakeholders impacted by DHT integration. Key findings revealed that DHTs enhanced treatment adherence, healthcare utilization, and community engagement while expanding technology infrastructure for scaling interventions. Notable opportunities included support and training and improved data quality. However, challenges such as operational and logistical barriers, inadequate network coverage, and cultural and gender sensitivity issues were prevalent. Strategies to address these challenges focused on continuous training for healthcare workers, community involvement to foster engagement, and data reporting and quality improvements. Despite their potential to transform healthcare delivery, particularly in underserved areas, successful integration of DHTs in Nigeria requires addressing infrastructure gaps, cultural norms, and operational challenges. Community engagement, capacity building for healthcare workers, and data-driven decision-making are critical to maximizing the impact of digital health interventions in Nigeria.

4 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
COChika Kingsley Onwuamah
Chika Kingsley Onwuamah
AOAzuka Patrick Okwuraiwe
Azuka Patrick Okwuraiwe
OSOlumuyiwa B. Salu
Olumuyiwa B. Salu
JSJoseph O. Shaibu
Joseph O. Shaibu
NNNnaemeka Ndodo
Nnaemeka Ndodo
RARosemary Audu
Rosemary Audu
A key element in containing the spread of the SARS-CoV-2 infection is quality diagnostics which is affected by several factors. We now report the comparative performance of five real-time diagnostic assays. Nasopharyngeal swab samples were obtained from persons seeking a diagnosis for SARS-CoV-2 infection in Lagos, Nigeria. The comparison was performed on the same negative, low, and high-positive sample set, with viral RNA extracted using the Qiagen Viral RNA Kit. All five assays are one-step reverse transcriptase real-time PCR assays. Testing was done according to each assay’s manufacturer instructions for use using real-time PCR platforms. 63 samples were tested using the five qPCR assays, comprising of 15 negative samples, 15 positive samples (Ct = 16–30; one Ct = 35), and 33 samples with Tib MolBiol E-gene Ct value ranging from 36–41. All assays detected all high positive samples correctly. Three assays correctly identified all negative samples while two assays each failed to correctly identify one different negative sample. The consistent detection of positive samples at different Ct/Cq values gives an indication of when to repeat testing and/or establish more stringent in-house cut-off value. The varied performance of different diagnostic assays, mostly with emergency use approvals, for a novel virus is expected. Comparative assays’ performance reported may guide laboratories to determine both their repeat testing Ct/Cq range and/or cut-off value.

AOAzuka Patrick Okwuraiwe
Azuka Patrick Okwuraiwe
COChizaram A. Onyeaghala
Chizaram A. Onyeaghala
OOObiageli Theresa Ozoude
Obiageli Theresa Ozoude
MSMuritala Suleiman
Muritala Suleiman
SASamirah Abdu-Aguye
Samirah Abdu-Aguye
OSOlajide Odunayo Sobande
Olajide Odunayo Sobande
Lassa fever (LF) is an acute viral hemorrhagic fever that poses a substantial public health security threat in West Africa. The non-specific clinical presentation of LF, coupled with a lack of reliable point-of-care diagnostics, means delayed diagnosis, leading to severe complications and mortality during epidemics. A systematic review and meta-analyses were performed by conducting an extensive online search using PubMed, Web of Science, Scopus, CINAHL, and Google Scholar (PROSPERO protocol identifier number CRD42024587426). Only peer-reviewed studies written in English were included in publications from 1 September 2014, to 31 August 2024. The analysis and reporting followed PRISMA guidelines. The quality of the included studies was assessed using the critical appraisal tools developed from the Joanna Briggs Institute Systematic Review Checklist for cohort studies. We included 19 studies that contained data from 4177 patients hospitalized with LF of any age. Most included studies employed a retrospective cohort design and were conducted in Nigeria (16/19; 84.2%). The mortality rate was highest in a Sierra Leonean study (63.0%), whereas a group-based analysis of Nigerian studies using a random-effects model identified Owo as having the highest mortality rate of 13% (95% CI: 6–23; I2 = 98%). The pooled mortality rate for severe LF was 19% (95% confidence interval [CI]:10–32). The most common complications of LF are acute kidney injury (AKI) at a pooled proportion of 19% (95% CI; 13–26; I2 = 89%)), followed by abnormal bleeding at a pooled proportion of 17% (95% CI; 9–30; I2 = 98%), and central nervous system (CNS) dysfunction at a pooled proportion of 15% (95% CI; 6–32; I2 = 98%). With one out of every five hospitalized LF patients likely to die in West Africa, accelerating the development of rapid diagnostic tests, licensed vaccines, and novel therapeutics is crucial. Strengthening community engagement and risk communication, developing regional treatment guidelines, decentralizing LF care units, and training healthcare workers using a harmonized curriculum will enhance early diagnosis and effective case management, thereby reducing severe complications and mortality.

10 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AOAzuka Patrick Okwuraiwe
Azuka Patrick Okwuraiwe
COChika Kingsley Onwuamah
Chika Kingsley Onwuamah
JSJoseph Ojonugwa Shaibu
Joseph Ojonugwa Shaibu
SASamuel Olufemi Amoo
Samuel Olufemi Amoo
FIFehintola Anthonia Ige
Fehintola Anthonia Ige
RARosemary Ajuma Audu
Rosemary Ajuma Audu
The present global pandemic triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has lingered for over a year in its devastating effects. Diagnosis of coronavirus disease 2019 (COVID-19) is currently established with a polymerase chain reaction (PCR) test by means of oropharyngeal-, nasopharyngeal-, anal-swabs, sputum and blood plasma. However, oral and nasal swabs are more commonly used. This study, therefore, assessed sensitivity and specificity of plasma as a diagnostic in comparison with a combination of oral and nasal swab samples, and the implications for blood transfusion. Oropharyngeal (OP) and nasopharyngeal (NP) swab samples were obtained from 125 individuals suspected to have COVID-19 and stored in viral transport medium (VTM) tubes. Ten millilitres of blood samples in EDTA were also obtained by venepuncture and spun to obtain plasma. Viral RNA was obtained from both swabs and plasma by manual extraction with Qiagen QIAamp viral RNA Mini Kit. Detection was done using a real time fluorescent RT-qPCR BGI kit, on a QuantStudio 3 real-time PCR instrument. Average age of study participants was 41 years, with 74 (59.2%) being male. Out of the 125 individuals tested for COVID-19, 75 (60%) were positive by OP/NP swab. However, only 6 (4.8%) had a positive plasma result for COVID-19 with median Ct value of 32.4. Sensitivity and specificity of RT-PCR SARS-CoV-2 test using plasma was 8% and 100% respectively. There was no false positive recorded, but 69 (55.2%) false negatives were obtained by plasma. SARS-CoV-2 viral RNA was detected, albeit low (4.8%) in plasma. Plasma is likely not a suitable biological sample to diagnose acute SARS-CoV-2 infection. The implication of transfusing blood in this era of COVID-19 needs further investigations.

1 January 2021 in PAMJ - One Health
Verified
Journal Article
Open access
AJAyorinde James
Ayorinde James
OSOlumuyiwa Babalola Salu
Olumuyiwa Babalola Salu
JSJoseph Ojonugwa Shaibu
Joseph Ojonugwa Shaibu
COChika Kingsley Onwuamah
Chika Kingsley Onwuamah
BMBamidele Paul Mutiu
Bamidele Paul Mutiu
SOSunday Aremu OMILABU
Sunday Aremu OMILABU
INTRODUCTION: Heightened surveillance of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 2019 outbreak in Wuhan, China activated several collaborative laboratory drills on its detection by health institutions in Nigeria. We hereby detail the laboratory detection and confirmation of the novel SARS-CoV-2 virus of the index case imported into Nigeria. METHODS: viral RNA from sputum sample of the index case was tested for SARS-CoV-2 envelope (E) and RNA dependent RNA polymerase (RdRp) genes using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Genetic analysis using a partial sequence of RdRp gene was used for laboratory confirmation, evolutionary inferences, and relatedness to previous strains of betacoronaviruses in Nigeria. RESULTS: both qRT-PCR for the E and RdRp genes indicated the presence of the SARS-CoV-2 RNA by showing cycle threshold (ct) values of 20.27 and 25.26 respectively. On successful completion of the sequencing run, data aligned with >98% similarity of the 2019 circulating strain of Coronavirus SARS-CoV-2. Evolutionary algorithms revealed that the sequence (RdRp gene) of the outbreak circulating strains were more conserved unlike previous coronavirus outbreaks. Data showed that some coronaviruses belonging to the BetaCoV genus had earlier been reported in bats and camels in Nigeria indicating the possibility of sero-protection in exposed populations. CONCLUSIONS: pre-laboratory drills prompted early diagnosis and confirmation of SARS-CoV-2 index case in Nigeria initiating rapid case-definition, contact tracing, and successful epidemiological management of the outbreak. Rapid sequencing of the viral genome during strategic points of the outbreak curve and making libraries of new variants for improved vaccine development are recommended.